These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38203473)

  • 21. Integrative effects of dystrophin loss on metabolic function of the mdx mouse.
    Strakova J; Kamdar F; Kulhanek D; Razzoli M; Garry DJ; Ervasti JM; Bartolomucci A; Townsend D
    Sci Rep; 2018 Sep; 8(1):13624. PubMed ID: 30206270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Live-imaging of revertant and therapeutically restored dystrophin in the Dmd
    Petkova MV; Stantzou A; Morin A; Petrova O; Morales-Gonzalez S; Seifert F; Bellec-Dyevre J; Manoliu T; Goyenvalle A; Garcia L; Richard I; Laplace-Builhé C; Schuelke M; Amthor H
    Neuropathol Appl Neurobiol; 2020 Oct; 46(6):602-614. PubMed ID: 32573804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
    Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
    Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Creation of a Novel Humanized Dystrophic Mouse Model of Duchenne Muscular Dystrophy and Application of a CRISPR/Cas9 Gene Editing Therapy.
    Young CS; Mokhonova E; Quinonez M; Pyle AD; Spencer MJ
    J Neuromuscul Dis; 2017; 4(2):139-145. PubMed ID: 28505980
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term effect of human mini-dystrophin in transgenic mdx mice improves muscle physiological function.
    Chu X; Li J; Qiao C; Wang J; Wang Y; Jiang XC; You H; Xiao X; Wang B
    FASEB J; 2021 Jun; 35(6):e21628. PubMed ID: 33982338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Duchenne muscular dystrophy: pathogenesis and promising therapies.
    Chang M; Cai Y; Gao Z; Chen X; Liu B; Zhang C; Yu W; Cao Q; Shen Y; Yao X; Chen X; Sun H
    J Neurol; 2023 Aug; 270(8):3733-3749. PubMed ID: 37258941
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Repression of phosphatidylinositol transfer protein α ameliorates the pathology of Duchenne muscular dystrophy.
    Vieira NM; Spinazzola JM; Alexander MS; Moreira YB; Kawahara G; Gibbs DE; Mead LC; Verjovski-Almeida S; Zatz M; Kunkel LM
    Proc Natl Acad Sci U S A; 2017 Jun; 114(23):6080-6085. PubMed ID: 28533404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exon skipping quantification by quantitative reverse-transcription polymerase chain reaction in Duchenne muscular dystrophy patients treated with the antisense oligomer eteplirsen.
    Anthony K; Feng L; Arechavala-Gomeza V; Guglieri M; Straub V; Bushby K; Cirak S; Morgan J; Muntoni F
    Hum Gene Ther Methods; 2012 Oct; 23(5):336-45. PubMed ID: 23075107
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological Inhibition of PKCθ Counteracts Muscle Disease in a Mouse Model of Duchenne Muscular Dystrophy.
    Marrocco V; Fiore P; Benedetti A; Pisu S; Rizzuto E; Musarò A; Madaro L; Lozanoska-Ochser B; Bouché M
    EBioMedicine; 2017 Feb; 16():150-161. PubMed ID: 28089792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new model mouse for Duchenne muscular dystrophy produced by 2.4 Mb deletion of dystrophin gene using Cre-loxP recombination system.
    Kudoh H; Ikeda H; Kakitani M; Ueda A; Hayasaka M; Tomizuka K; Hanaoka K
    Biochem Biophys Res Commun; 2005 Mar; 328(2):507-16. PubMed ID: 15694376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced expression of the alpha 7 beta 1 integrin reduces muscular dystrophy and restores viability in dystrophic mice.
    Burkin DJ; Wallace GQ; Nicol KJ; Kaufman DJ; Kaufman SJ
    J Cell Biol; 2001 Mar; 152(6):1207-18. PubMed ID: 11257121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy.
    Li S; Kimura E; Ng R; Fall BM; Meuse L; Reyes M; Faulkner JA; Chamberlain JS
    Hum Mol Genet; 2006 May; 15(10):1610-22. PubMed ID: 16595609
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of disease specific pathways using in vivo SILAC proteomics in dystrophin deficient mdx mouse.
    Rayavarapu S; Coley W; Cakir E; Jahnke V; Takeda S; Aoki Y; Grodish-Dressman H; Jaiswal JK; Hoffman EP; Brown KJ; Hathout Y; Nagaraju K
    Mol Cell Proteomics; 2013 May; 12(5):1061-73. PubMed ID: 23297347
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Natural History of a Mouse Model Overexpressing the Dp71 Dystrophin Isoform.
    Lim KRQ; Shah MNA; Woo S; Wilton-Clark H; Zhabyeyev P; Wang F; Maruyama R; Oudit GY; Yokota T
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy.
    Amoasii L; Long C; Li H; Mireault AA; Shelton JM; Sanchez-Ortiz E; McAnally JR; Bhattacharyya S; Schmidt F; Grimm D; Hauschka SD; Bassel-Duby R; Olson EN
    Sci Transl Med; 2017 Nov; 9(418):. PubMed ID: 29187645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Electrical impedance myography detects dystrophin-related muscle changes in mdx mice.
    Hiyoshi T; Zhao F; Baba R; Hirakawa T; Kuboki R; Suzuki K; Tomimatsu Y; O'Donnell P; Han S; Zach N; Nakashima M
    Skelet Muscle; 2023 Nov; 13(1):19. PubMed ID: 37980539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of Therapeutic Potential of a Dual AAV Approach for Duchenne Muscular Dystrophy.
    Albini S; Palmieri L; Dubois A; Bourg N; Lostal W; Richard I
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511179
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-Term Biodistribution and Safety of Human Dystrophin Expressing Chimeric Cell Therapy After Systemic-Intraosseous Administration to Duchenne Muscular Dystrophy Model.
    Siemionow M; Brodowska S; Langa P; Zalants K; Kozlowska K; Grau-Kazmierczak W; Heydemann A
    Arch Immunol Ther Exp (Warsz); 2022 Aug; 70(1):20. PubMed ID: 35978142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression and localization of protein inhibitor of neuronal nitric oxide synthase in Duchenne muscular dystrophy.
    Guo Y; Petrof BJ; Hussain SN
    Muscle Nerve; 2001 Nov; 24(11):1468-75. PubMed ID: 11745948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the dystrophin carboxy-terminal domain for micro-dystrophin gene therapy in cardiac and skeletal muscles in the DMD
    Bourdon A; François V; Zhang L; Lafoux A; Fraysse B; Toumaniantz G; Larcher T; Girard T; Ledevin M; Lebreton C; Hivonnait A; Creismeas A; Allais M; Marie B; Guguin J; Blouin V; Remy S; Anegon I; Huchet C; Malerba A; Kao B; Le Heron A; Moullier P; Dickson G; Popplewell L; Adjali O; Montanaro F; Le Guiner C
    Gene Ther; 2022 Sep; 29(9):520-535. PubMed ID: 35105949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.